Flag­ship and the Cys­tic Fi­bro­sis Foun­da­tion team up on a nov­el re­search pact to chase down po­ten­tial cures

Amid Mod­er­na’s quick rise to the top, the in­vestor be­hind the firm, Flag­ship Pi­o­neer­ing, has nev­er been more promi­nent or un­shake­ably con­fi­dent. Now, look­ing to crack the code on a cure for cys­tic fi­bro­sis, the uber-in­cu­ba­tor is part­ner­ing up with a lead­ing non­prof­it to chase the im­pos­si­ble.

Flag­ship’s Pi­o­neer­ing Med­i­cines unit and the Cys­tic Fi­bro­sis Foun­da­tion will team up on a nov­el in­dus­try-non­prof­it col­lab­o­ra­tion to pur­sue ther­a­peu­tic break­throughs in the crip­pling lung dis­ease, with the non­prof­it pony­ing up $110 mil­lion in R&D fund­ing for a planned new­co, the part­ners said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER